Board of Directors

Anders Essen-Möller

Chairman

Born in 1941. M.Sc. Founder of and CEO during 1996-2007 of Diamyd Medical and Chairman 2007 –2015. Independent of the Company, major owner. Founder of Synectics Medical AB, sold to Medtronic, Inc. in 1996. Chairman of NextCell Pharma AB.

Holdings in Diamyd Medical as of December 31, 2023: 741 630 A-shares and 3 017 040 B-shares. 185 407 TO3A, 185 407 TO4A, 638 416 TO3B, 638 416 TO4B. 1 687 666 B-shares via an endowment policy.

Erik Nerpin

Vice Chairman

Born in 1961. Lawyer. Self-employed with Advokatfirman Nerpin AB. Independent of the Company and its principal owners. Board member since 2012. Chairman of Kancera AB and Blasieholmen Investment Group AB and Board member in among others Effnetplattformen AB.

Holdings in Diamyd Medical as of December 31, 2023: 70 731 B-shares. 12 000 TO3B, 12 000 TO4B.

Maria-Teresa Essen-Möller

Board Member

Born in 1970. M.Sc. in Business Administration. Independent to the Company, not independent to its principal owners. Chief Commercial Officer at ScientificMed AB. Previous experience include CEO of Health Solutions AB, Digital Marketing Manager at Sanofi and Account Director at Creuna. Board member since 2009.

Holdings in Diamyd Medical as of December 31, 2023: 400 000 A-shares, 963 998 B-shares.

Torbjörn Bäckström

Board Member

Born in 1948. MD, PhD. CEO of Umecrine AB. Independent of the Company and its principal owners. Board member since 2017. Head of Neurosteroid Research Centre in Umeå and Senior Professor in the Department of Clinical Science, Obstetrics and Gynecology at Umeå University.

Holdings in Diamyd Medical as of December 31, 2023: 1 000 B-shares via company.

Mark Atkinson

Board Member

Born in 1961. PhD. Professor of Diabetes Research, Department of Pathology, Immunology and Laboratory Medicine, University of Florida, USA. American Diabetes Association Eminent Scholar for Diabetes Research. Director, UF Diabetes Institute, University of Florida. Independent of the Company and its principal owners. Board member since 2018.

Holdings in Diamyd Medical as of December 31, 2023: 16 750 B-shares.

Karin Hehenberger

Board Member

Born in 1972. M.D., Ph.D, Karolinska Institute, Post-doc at the Joslin center, Harvard Medical School. Founder and CEO of Lyfebulb, Member of the 3B Future Health Ventures Scientific Advisory board, Board member AADI pharmaceuticals (Nasdaq), Board member Anacardio AB, Board member Rolf Luft Foundation for Diabetes research, Board member American Diabetes Association NY/NJ Community Board. Independent to the Company and its principal owners. Board member since 2021.

Holdings in Diamyd Medical as of December 31, 2023: 10 000 B-shares.

Karin Rosén

Board Member

Born in 1967. M.D., Ph.D, Lund University, Sweden. More than two decades of experience from senior leadership positions in Global Clinical Development and US & Global Medical Affairs with Horizon Therapeutics, GlaxoSmithKline, Aimmune Therapeutics and Genentech, part of the Roche group. Independent of the Company and its principal owners. Adjunct Board member since March 2023.

Holdings in Diamyd Medical as of December 31, 2023: -

Management

Ulf Hannelius

Chief Executive Officer

Born in 1975. PhD in Molecular Biology from Karolinska Institutet in Stockholm and Executive MBA from Stockholm School of Economics. Prior experience from business development in the biotech and medtech industries as well as from academic research in the fields of genetics and molecular biology. Chairman of Diamyd Biomanufacturing AB, Board member in MainlyAI AB. Joined Diamyd Medical in 2015, CEO since 2016.

Holdings in Diamyd Medical as of December 31, 2023: 320 840 B-shares. 83 340 TO3B, 83 340 TO4B.

Martina Widman

Chief Operating Officer

Born in 1981. M.Sc. in Mechanical Engineering from the Royal Institute of Technology in Stockholm, with a specialization in Biomedical Engineering. Prior experience of clinical operation from the pharmaceutical industry. Joined Diamyd Medical in 2008.

Holdings in Diamyd Medical as of December 31, 2023: 12 500 B-shares.

Anna Styrud

Chief Financial Officer

Born in 1961. B.Sc. in Business Administration from Uppsala University. Prior experience include Treasurer of Vasakronan AB and various positions in finance and control within real estate and engineering industry. Board member in Diamyd Biomanufacturing AB. Joined Diamyd Medical in 2010.

Holdings in Diamyd Medical as of December 31, 2023: 147 499 B-shares. 10 000 TO3B, 10 000 TO4B.

Anton Lindqvist

Chief Scientific Officer

Born in 1980. M.Sc in Molecular Biotechnology Engineering from Uppsala University. Research experience from University of Pittsburgh, Uppsala University, the Royal Institute of Technology and Karolinska Institutet. Prior experience in managing technical development at several bio-tech companies. Joined Diamyd Medical in 2013.

Holdings in Diamyd Medical as of December 31, 2023: -

Maja Johansson

Chief Operating Officer, Manufacturing Site

Born in 1962. PhD in Biochemistry from Umeå University and Associate professor in neuroendocrinology. Prior experience from biotech companies. Board member in Diamyd Biomanufacturing AB. Joined Diamyd Medical in 2020.

Holdings in Diamyd Medical as of December 31, 2023: 3 333 B-shares, 833 TO3B, 833 TO4B.

Christoph Nowak

Chief Medical and Business Officer

Born in 1986. PhD in molecular epidemiology from Uppsala University, MD from University of Oxford (UK), combined Bachelor-Master in Psychology from Braunschweig University (Germany). Prior experience includes Assistant Professor at Karolinska Institutet and physician at Raigmore Hospital in Inverness (Scotland). Board member in OncoZenge AB and Osher v'Chedvah AB. Consultant role as chief medical officer at Melius Pharma AB. Joined Diamyd Medical in 2021.

Holdings in Diamyd Medical as of December 31, 2023: 11 880 B-shares, 2 970 TO3B, 2 970 TO4B. 796 B-shares, 199 TO3B and 199 TO4B in an endowment policy.



Order GAD for preclinical research

GAD PRODUCTS